Literature DB >> 27921338

Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression.

Pim Cuijpers1,2, Erica Weitz1,2, Femke Lamers2,3, Brenda W Penninx2,3, Jos Twisk2, Robert J DeRubeis4, Sona Dimidjian5, Boadie W Dunlop6, Robin B Jarrett7, Zindel V Segal8, Steven D Hollon9.   

Abstract

BACKGROUND: Melancholic and atypical depression are widely thought to moderate or predict outcome of pharmacological and psychological treatments of adult depression, but that has not yet been established. This study uses the data from four earlier trials comparing cognitive behavior therapy (CBT) versus antidepressant medications (ADMs; and pill placebo when available) to examine the extent to which melancholic and atypical depression moderate or predict outcome in an "individual patient data" meta-analysis.
METHODS: We conducted a systematic search for studies directly comparing CBT versus ADM, contacted the researchers, integrated the resulting datasets from these studies into one big dataset, and selected the studies that included melancholic or atypical depressive subtyping according to DSM-IV criteria at baseline (n = 4, with 805 patients). After multiple imputation of missing data at posttest, mixed models were used to conduct the main analyses.
RESULTS: In none of the analyses was melancholic or atypical depression found to significantly moderate outcome (indicating a better or worse outcome of these patients in CBT compared to ADM; i.e., an interaction), predict outcome independent of treatment group (i.e., a main effect), or predict outcome within a given modality. The outcome differences between patients with melancholia or atypical depression versus those without were consistently very small (all effect sizes g < 0.10).
CONCLUSIONS: We found no indication that melancholic or atypical depressions are significant or relevant moderators or predictors of outcome of CBT and ADM.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  antidepressants; atypical depression; cognitive behavior therapy; melancholia; meta-analysis

Mesh:

Substances:

Year:  2016        PMID: 27921338     DOI: 10.1002/da.22580

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  5 in total

1.  Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.

Authors:  Boadie W Dunlop; Justin K Rajendra; W Edward Craighead; Mary E Kelley; Callie L McGrath; Ki Sueng Choi; Becky Kinkead; Charles B Nemeroff; Helen S Mayberg
Journal:  Am J Psychiatry       Date:  2017-03-24       Impact factor: 18.112

2.  A Propensity Score Analysis of Homework Adherence-Outcome Relations in Cognitive Behavioral Therapy for Depression.

Authors:  Judith A Callan; Nikolaos Kazantzis; Seo Young Park; Charity G Moore; Michael E Thase; Abu Minhajuddin; Sander Kornblith; Greg J Siegle
Journal:  Behav Ther       Date:  2018-06-05

3.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

Review 4.  Atypical depression: current perspectives.

Authors:  Dorota Łojko; Janusz K Rybakowski
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-20       Impact factor: 2.570

5.  Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines.

Authors:  Martin Plöderl; Michael P Hengartner
Journal:  BMC Psychiatry       Date:  2019-09-02       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.